Drug Type Small molecule drug |
Synonyms Loxapine, Loxapine succinate (USP), 琥珀酸洛沙平 + [7] |
Target |
Action antagonists |
Mechanism 5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), DRDs antagonists(Dopamine receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (25 Feb 1975), |
Regulation- |
Molecular FormulaC22H24ClN3O5 |
InChIKeyYQZBAXDVDZTKEQ-UHFFFAOYSA-N |
CAS Registry27833-64-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00794 | Loxapine Succinate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Schizophrenia | United States | 25 Feb 1975 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | Phase 2 | United States | 01 Jun 2007 | |
Pulmonary Disease, Chronic Obstructive | Phase 1 | United States | 01 Jun 2009 | |
Asthma | Phase 1 | United States | 01 May 2009 |
Phase 1 | - | 30 | Loxapine (Inhaled Loxapine) | ogjdbkrhbm(isiqqzxavl) = sbockgwnyr kcqjyktfkj (gsjgklsixz, xpgmpgiafb - brmgjekaej) View more | - | 11 Mar 2019 | |
Staccato Placebo (Inhaled Staccato Placebo) | ogjdbkrhbm(isiqqzxavl) = aruodwmdyl kcqjyktfkj (gsjgklsixz, rqcztwtsmw - skayjavkze) |